To ensure this doesn't happen in the future, please enable Javascript and cookies in your browser. If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

Question-and-Answer Session Maybe to start, there was some news last week, not from you guys, but from Fulcrum, which was an update that has obviously been top of mind given the mechanism of action overlap. Maybe you could speak to the Fulcrum update on pociredir and any potential implications for your program in prostate cancer rinzimetostat. Yes. Firstly, thanks for having us here at the conference. So it's a great conference. We're just talking about the long flight across the country. So at a high level ...

CEO & Director Yes. Thank you for asking, and thank you all for being here. Quality of Medline is paramount, right? Patient safety is the most important thing that we focus on each and every day. And the most recent warning letter was from our ReadyCare Waukegan facility, which is where we make CHT wipes, which is a pre-surgical antiseptic. This goes back to October. We actually informed the FDA that we found some things we were not happy with. We actually closed the factory down. So the warning letter was ...

市场与行业背景 - 公司运营于一个增长的市场 因为电力需求远超公用事业公司扩大电网发电以支持美国再工业化和大型数据中心发展的能力 [1] 分析师背景 - 分析师Michael Del Monte是买方股票分析师 在科技、能源、工业和材料领域拥有专业知识 [1] - 在进入投资管理行业之前 该分析师在专业服务领域工作超过十年 行业经验涵盖石油与天然气、油田服务、中游、工业、信息技术、工程总承包服务和可选消费品 [1]

文章核心观点 - 英特尔(INTC)的叙事已不再仅仅是制造业务的扭亏为盈，而是更多地转向底层AI基础设施的结构性变革[1] - 行业正朝着AI推理和智能体AI方向发展，这正使得CPU发挥重要作用[1] 分析师背景与投资方法论 - 分析师Yiannis拥有德勤和毕马威的外部/内部审计及咨询工作经验，是ACCA全球资深会员，并拥有英国商学院的学士和硕士学位[1] - 其投资风格是在公司爆发前发现高潜力赢家，专注于不对称机会（上行潜力至少是下行风险的3-5倍）[1] - 通过利用市场无效性和逆向洞察，寻求在防范资本减值的同时最大化长期复利[1] - 风险管理至关重要，寻求足够的安全边际以保护资本，同时最大化长期复利[1] - 投资期限为2-3年，以度过市场波动，确保耐心、纪律和智能的资本配置能随时间带来超额回报[1]

公司业绩与展望 - 公司对2026年第一季度业绩表示满意，认为2026年是公司发展的跳板年[3] - 第一季度营收同比增长6%，非GAAP每股收益同比增长5%[4] - 公司预计快速增长的产品将抵消地舒单抗产品线面临竞争加剧的影响，且这一动态在第一季度已显现[3] 产品表现 - 第一季度有16款产品实现了两位数或更高的销售增长[4] - 目前有17款产品的年化销售额达到或超过5亿美元[4] 公司管理与战略 - 公司强调其严谨的财务管理是长期以来的标志[4] - 公司相信存在多种成功路径，尤其是对患者而言[3]

Question-and-Answer Session We're coming on the back of ADA. What did you learn over the weekend? And how does that kind of inform your view of the obesity landscape as it stands today? CEO & Director So one, we had a great ADA just coming from New Orleans. We -- Dr. Julio Rosenstock gave the opening lecture with our data, our ACCESS data. And I think what we sort of took home from that, we also had a Nature Medicine publication that came out simultaneously to the presentation on Friday of ADA. We clearly c ...

Presentation Good morning, everyone, and welcome. I'll be acting as Chair of today's meeting. With me on this virtual call are Paul Goddard, the President and CEO of Pizza Pizza Limited; and Christine D'Sylva, CFO of Pizza Pizza Limited. We want to thank you for joining us on this virtual platform. Instructions on how to ask questions and the voting procedure will appear on your screens. Please note though, only duly appointed proxy holders and shareholders are able to ask questions and vote. As investors, ...

Apollo sees little evidence that AI is displacing workers. (0:15) J.M. Smucker rallies after sales edge past forecasts. (1:19). Shipowners order record oil supertankers as conflict lifts rates. (2:17) This is an abridged transcript of the podcast: Our top story so far, concerns that artificial intelligence could trigger widespread job losses have yet to materialize in the U.S. labor market. Apollo Chief Economist Torsten Slok argues that current employment data show little evidence of workers being displace ...

CEO & Chairman of the Board Question-and-Answer Session Maybe to start, if you could provide us an overview of your company for those who may not be familiar, including the updates that we'll see within the next year. David Hallal The first anti-myostatin inhibitor went into the clinic in 2004, 2005. And really, over the period of these last 20- some years, there have been multiple myostatin inhibitors that have failed in clinical development. We stand alone with our unique technology platform and approach ...